Novo Nordisk has reduced the U.S. out-of-pocket cost for Ozempic to $499 per month for uninsured customers—and it’s available through direct delivery and more than 70,000 pharmacies nationwide. This marks a dramatic drop from the list price of approximately $1,000–$1,350.
Direct-to-Consumer Access via NovoCare & GoodRx
The launch extends Novo’s NovoCare direct-to-consumer platform, first introduced for Wegovy, to now include Ozempic. Patients can order and receive the medication at home. In addition, Ozempic is accessible at cash price through major retail pharmacies using GoodRx coupons.
Why This Price Drop Matters
-
Filling an access gap: Though about 98% of Ozempic users benefit from insurance or low copays, the uninsured or underinsured still face high barriers.
-
Combating counterfeit substitutes: Greater accessibility of the authentic drug helps deter the use of unsafe, unapproved "knockoff" versions circulating in the market.
Political and Market Impact
-
Revenues & stock: Novo Nordisk’s shares rose—6% in some reports—following the announcement, illustrating investor confidence in the strategy.
-
Regulatory momentum: This move aligns with broader pressure from policymakers and the administration to reduce drug costs and foster more direct-to-patient access.
0 Comments